A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach

Xiaomin Wang; Jian Chen; Josephine Reyes; Simon Zhou; Maria Palmisano; Yan Li

Journal ArticleOPEN ACCESS

A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach

Wang X
Chen J
Reyes J
et al.

Oncology and Therapy (2020) 8(1) 91-102

DOI: 10.1007/s40487-019-0097-7

N/ACitations

5Readers

Abstract

The purpose of this study was to evaluate the absolute bioavailability (BA) of AG-221 following a single oral dose of 100 mg AG-221 and an intravenous (IV) dose of ~ 100 μg AG-221 containing approximately 300 nCi of [14C]-AG-221.

Cite

CITATION STYLE

APA

Wang, X., Chen, J., Reyes, J., Zhou, S., Palmisano, M., & Li, Y. (2020). A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach. Oncology and Therapy, 8(1), 91–102. https://doi.org/10.1007/s40487-019-0097-7

A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach

Abstract

Cite

Register to see more suggestions